Literature DB >> 8807203

Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

S M Callister1, D A Jobe, R F Schell, C S Pavia, S D Lovrich.   

Abstract

The serodiagnosis of early Lyme disease has been plagued with problems of sensitivity and specificity. We found that the flow-cytometric borreliacidal-antibody test had a sensitivity of 72% for the detection of patients with early Lyme disease. By contrast, the sensitivity of the enzyme immunofluorescence assay was 28%. The enhanced sensitivity of the borreliacidal-antibody test was due to the use of Borrelia burgdorferi 50772, which lacks OspA and OspB. When B. burgdorferi 297, which expresses both OspA and OspB, was used, the sensitivity of the borreliacidal-antibody test was 15%. Our results also showed that the borreliacidal-antibody test was specific. No borreliacidal activity was detected in normal sera or in sera from patients with mononucleosis, rheumatoid factor, or syphilis. These results demonstrate that the flow-cytometric borreliacidal-antibody test may be the laboratory "gold standard" for the serodiagnosis of Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807203      PMCID: PMC170357          DOI: 10.1128/cdli.3.4.399-402.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  37 in total

1.  Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi.

Authors:  R A Kalish; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

2.  The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies.

Authors:  M Scriba; J S Ebrahim; T Schlott; H Eiffert
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

3.  Monoclonal antibodies with in vitro borreliacidal activities define the outer surface proteins A and B of Borrelia burgdorferi.

Authors:  M Moskophidis; B Luther
Journal:  Zentralbl Bakteriol       Date:  1993-06

4.  Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement.

Authors:  V Sambri; S Armati; R Cevenini
Journal:  FEMS Immunol Med Microbiol       Date:  1993-06

5.  Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi.

Authors:  S J Padula; A Sampieri; F Dias; A Szczepanski; R W Ryan
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis.

Authors:  R W Lightfoot; B J Luft; D W Rahn; A C Steere; L H Sigal; D C Zoschke; P Gardner; M C Britton; R L Kaufman
Journal:  Ann Intern Med       Date:  1993-09-15       Impact factor: 25.391

7.  The overdiagnosis of Lyme disease.

Authors:  A C Steere; E Taylor; G L McHugh; E L Logigian
Journal:  JAMA       Date:  1993-04-14       Impact factor: 56.272

8.  Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.

Authors:  S M Callister; R F Schell; K L Case; S D Lovrich; S P Day
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

9.  In vitro inhibition of Borrelia burgdorferi growth by antibodies.

Authors:  A Sadziene; P A Thompson; A G Barbour
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

10.  Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection.

Authors:  V Preac-Mursic; B Wilske; E Patsouris; S Jauris; G Will; E Soutschek; S Rainhardt; G Lehnert; U Klockmann; P Mehraein
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

View more
  21 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 2.  Laboratory testing for Lyme disease: possibilities and practicalities.

Authors:  Kurt D Reed
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits borreliacidal antibody production.

Authors:  Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Joseph Kuo; Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

5.  Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early lyme borreliosis from OspA vaccination.

Authors:  C A Wieneke; S D Lovrich; S M Callister; D A Jobe; J A Marks; R F Schell
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody.

Authors:  M C Remington; E L Munson; S M Callister; M L Molitor; J A Christopherson; D J DeCoster; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Authors:  Steven D Lovrich; Dean A Jobe; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

8.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

9.  Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species.

Authors:  Nicholas J Kotloski; Dean T Nardelli; Sara Heil Peterson; Jose R Torrealba; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

10.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.